These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 3709269)

  • 21. Azlocillin treatment of urinary tract infection in patients on haemodialysis.
    Hallan H; Svarva PL; Svartås TM; Widerøe T
    Scand J Infect Dis Suppl; 1981; 29():55-8. PubMed ID: 6947406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of acute and chronic urological infections with azlocillin--clinical and microbiological research].
    Minkov N; Zlatanov Z; Zozikov B; Atanasova M
    Vutr Boles; 1985; 24(1):54-62. PubMed ID: 4024609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacokinetics of azlocillin in critical conditions: an individualized schedule of drug administration in relation to anatomo-physiologic and pathologic factors].
    Firsov AA; Nasonov VN; Mura'veva SA; Kruglov AA
    Antibiot Khimioter; 1989 Aug; 34(8):620-4. PubMed ID: 2589904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of neonatal sepsis with ceftriaxone/gentamicin and with azlocillin/gentamicin: a clinical comparison of efficacy and tolerability.
    Wiese G
    Chemotherapy; 1988; 34(2):158-63. PubMed ID: 3391053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concentration of azlocillin in human chondral tissue.
    Schönfeld W; Knöller J; Bremm KD; Meier H; König W
    Zentralbl Bakteriol Mikrobiol Hyg A; 1988 Mar; 267(4):537-40. PubMed ID: 3381602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An azlocillin dosing nomogram for renal insufficiency.
    Whelton A; Stout RL; Delgado FA
    J Antimicrob Chemother; 1983 May; 11 Suppl B():97-9. PubMed ID: 6619037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison between the combination of azlocillin-gentamicin and ampicillin-gentamicin in the treatment of a nursery population.
    Fogel D; Farfel L; Miskin A; Mogilner BM
    Isr J Med Sci; 1983 Nov; 19(11):1009-15. PubMed ID: 6662683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacokinetics after discontinuous intravenous administration of azlocillin].
    Naber K; Adam D
    Arzneimittelforschung; 1983; 33(3):429-32. PubMed ID: 6683518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elimination of azlocillin in patients with biliary t-tube drainage.
    Gundert-Remy U; Weber E
    Eur J Clin Pharmacol; 1982; 22(5):435-9. PubMed ID: 7117356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic comparison of 5 g of azlocillin every 8 h and 4 g every 6 h in healthy volunteers.
    Lander RD; Henderson RP; Pyszczynski DR
    Antimicrob Agents Chemother; 1989 May; 33(5):710-3. PubMed ID: 2751284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of azlocillin in children with cystic fibrosis.
    Bergan T; Michalsen H
    Arzneimittelforschung; 1979; 29(12a):1955-7. PubMed ID: 543899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dosage adjustment of antiinfective therapy in patients with renal impairment.
    Eckhardt A; Borner K; Keller F; Zellner D
    Int J Clin Pharmacol Ther; 1997 Mar; 35(3):99-102. PubMed ID: 9088997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacokinetics of azlocillin in the burn patient].
    Drugeon HB; Pannier M; Courtieu AL
    Presse Med; 1984 Mar; 13(13):805-7. PubMed ID: 6231599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of combination therapy with ciprofloxacin and azlocillin in intensive care patients with pneumonia and/or sepsis.
    Engelhardt D; Ruckdeschel G
    J Chemother; 1989 Jul; 1(4 Suppl):788-9. PubMed ID: 16312640
    [No Abstract]   [Full Text] [Related]  

  • 35. [Evaluation of the clinical activity of azlocillin. A multicenter study conducted in 14 centers].
    Konopka CA
    Presse Med; 1984 Mar; 13(13):808-11. PubMed ID: 6231600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antimicrobial effectiveness of azlocillin in cholesteatoma in parenteral administration].
    Mertens J; Wustrow J; Ullmann U
    HNO; 1988 Oct; 36(10):423-5. PubMed ID: 3230064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of azlocillin after intramuscular application.
    Holá V; Polívková L; Novák L
    Czech Med; 1986; 9(3):166-9. PubMed ID: 3095077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Azlocillin with and without an aminoglycoside against respiratory tract infections in children with cystic fibrosis.
    Michalsen H; Bergan T
    Scand J Infect Dis Suppl; 1981; 29():92-7. PubMed ID: 6947408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of azlocillin in neonates.
    Sitka U; Weingärtner L; Patsch R; Richter I
    Chemotherapy; 1980; 26(3):171-6. PubMed ID: 7363714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metronidazole: pharmacokinetic observations in severely ill patients.
    Ljungberg B; Nilsson-Ehle I; Ursing B
    J Antimicrob Chemother; 1984 Sep; 14(3):275-83. PubMed ID: 6490572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.